Evidence map›Paper›PMID 39663589›Full record

Trial reportAcademic emergency medicine : official journal of the Society for Academic Emergency Medicine2025

High-velocity nasal insufflation versus noninvasive positive pressure ventilation for moderate acute exacerbation of chronic obstructive pulmonary disease in the emergency department: A randomized clinical trial.

David P Yamane, Christopher W Jones, R Gentry Wilkerson, Joshua J Oliver, Soroush Shahamatdar, Aditya Loganathan, Taylor Bolden, Ryan Heidish, Connor L Kelly, Amy Bergeski and 4 more

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
In one paragraph

Trial report in Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David P YamaneDepartment of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Christopher W JonesDepartment of Emergency Medicine, Cooper University Healthcare, Camden, New Jersey, USA.ORCID 0000-0001-9704-9094
R Gentry WilkersonDepartment of Emergency Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Joshua J OliverDepartment of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington, USA.
Soroush ShahamatdarDepartment of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Aditya LoganathanDepartment of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Taylor BoldenDepartment of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Ryan HeidishDepartment of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Connor L KellyDepartment of Emergency Medicine, Madigan Army Medical Center, Joint Base Lewis-McChord, Tacoma, Washington, USA.
Amy BergeskiVapotherm, Inc., Exeter, New Hampshire, USA.
Jessica S WhittleVapotherm, Inc., Exeter, New Hampshire, USA.
George C DunganVapotherm, Inc., Exeter, New Hampshire, USA.
Richard MaisiakSchool of Medicine, University of Alabama of Birmingham, Birmingham, Alabama, USA.
Andrew C MeltzerDepartment of Emergency Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.ORCID 0000-0001-5971-8314

Funding

Vapotherm Inc
6 · The paper itself

Abstract

backgroundAcute exacerbations of chronic obstructive pulmonary disease (COPD) in the emergency department (ED) involve dyspnea, cough, and chest discomfort; frequent exacerbations are associated with increased mortality and reduced quality of life. Noninvasive positive pressure ventilation (NiPPV) is commonly used to help relieve symptoms but is limited due to patient intolerance. We aimed to determine whether high-velocity nasal insufflation (HVNI) is noninferior to NiPPV in relieving dyspnea within 4 h in ED patients with acute hypercapnic respiratory failure.

methodsThis randomized control trial was conducted in seven EDs in the United States. Symptomatic patients with suspected COPD, partial pressure of carbon dioxide (pCO

resultsSixty-eight patients were randomized between November 5, 2020, and May 10, 2023 (mean age 65.6 years; 47% women). The initial pCO

conclusionsIn participants with symptomatic COPD, HVNI was noninferior to NiPPV in relieving dyspnea 4 h after therapy initiation. HVNI may be a reasonable treatment option for some patients experiencing moderate acute exacerbations of COPD in the ED.

Indexed as

InsufflationNoninvasive VentilationPositive-Pressure RespirationPulmonary Disease, Chronic ObstructiveAgedDyspneaEmergency Service, HospitalFemaleHumansMaleMiddle AgedRespiratory InsufficiencyTreatment Outcome

Identifiers

PMID39663589
PMCPMC12017259

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.